Drug Profile
Atorvastatin/glimepiride/metformin
Alternative Names: GLC3GMALatest Information Update: 28 Apr 2018
Price :
$50
*
At a glance
- Originator GL PharmTech
- Class Amides; Antihyperglycaemics; Antihyperlipidaemics; Biguanides; Fatty acids; Fluorobenzenes; Heptanoic acids; Pyrroles; Small molecules; Sulfonylureas
- Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; HMG-CoA reductase inhibitors; Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hyperlipidaemia; Type 2 diabetes mellitus
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for research development in Hyperlipidaemia in South Korea (PO)
- 28 Apr 2018 No recent reports of development identified for research development in Type-2-diabetes-mellitus in South Korea (PO)
- 18 Mar 2014 Early research in Hyperlipidaemia in South Korea (PO)